Cascade Research: Leveraging AI to Improve Lung Cancer Screening for Women

Addressing an Urgent Public Health Issue

The Cascade research project focused on the crucial role of artificial intelligence (AI)
in improving lung cancer screening, particularly for women. This focus stemmed from a deeply concerning epidemiological situation: lung cancer is rapidly increasing among European women, with French women now representing 35% of all patients – a figure that has more than doubled in just two decades.

While the 2011 publication of the NLST trial demonstrated the benefits of low-dose computed tomography (LDCT) for lung cancer screening, European trials relied on double reading by radiologists to confirm results. This can be time-consuming and prone to human error. The Cascade research aimed to explore if AI, specifically deep learning algorithms, could serve as a reliable second reader, streamlining the process and potentially improving accuracy.

Prioritizing Women in Research

The decision to focus on women was multifaceted. Firstly, previous trials like NLST
significantly underrepresented women, comprising only 16% of participants. This lack of data necessitates further research specifically on female populations. Secondly, the dramatic increase in lung cancer prevalence among women underscores the urgency of addressing this public health crisis.

The Cascade project seeks to not only enhance lung cancer screening accuracy but also raise awareness about the alarming rise in this disease among women. By leveraging cutting-edge AI technology and focusing on a vulnerable population, this research holds significant promise for improving
early detection and ultimately saving lives.